

This week in techniques

Approach	Summary	Licensing status	Publication and contact information
Drug platforms			
Depletion of host hematopoietic stem cells (HSCs) <i>in utero</i> improves engraftment after liver mononuclear cell transplant in fetuses	<p>Mouse studies suggest <i>in utero</i> depletion of HSCs can improve engraftment after liver mononuclear cell transplant. In fetal mice, a mouse anti-stem cell factor receptor tyrosine kinase (c-Kit; Kit; Cd117) antibody was shown to deplete HSCs. In fetal mice, depletion of HSCs with the mouse antibody prior to congenic liver mononuclear cell transplantation increased the rate and level of donor cell engraftment compared with no depletion. Next steps include using a humanized version of the antibody in <i>in utero</i> nonhuman primate bone marrow transplant models of hemoglobinopathies, such as thalassemia or sickle cell disease.</p> <p>SciBX 7(27); doi:10.1038/scibx.2014.810 Published online July 17, 2014</p>	Patent and licensing status unavailable	<p>Derderian, S.C. <i>et al. Blood</i>; published online May 30, 2014; doi:10.1182/blood-2014-02-550327</p> <p>Contact: Tippi C. MacKenzie, University of California, San Francisco, Calif. e-mail: tippi.mackenzie@ucsfmedctr.org</p>